Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Feb;38(2):198-203.
doi: 10.1016/j.leukres.2013.11.009. Epub 2013 Nov 19.

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Francesca R Mauro  1 , Stefano Molica  2 , Luca Laurenti  3 , Agostino Cortelezzi  4 , Angelo M Carella  5 , Francesco Zaja  6 , Annalisa Chiarenza  7 , Francesco Angrilli  8 , Francesco Nobile  9 , Roberto Marasca  10 , Caterina Musolino  11 , Maura Brugiatelli  12 , Alfonso Piciocchi  13 , Marco Vignetti  13 , Paola Fazi  13 , Giuseppe Gentile  14 , Maria S De Propris  14 , Irene Della Starza  14 , Marilisa Marinelli  14 , Sabina Chiaretti  14 , Ilaria Del Giudice  14 , Mauro Nanni  14 , Francesco Albano  15 , Antonio Cuneo  16 , Anna Guarini  14 , Robin Foà  14 ; Gruppo Italiano Malattie EMatologiche dell’Adulto Working Party for Chronic Lymphoproliferative Disorders
Collaborators, Affiliations
Clinical Trial

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Francesca R Mauro et al. Leuk Res. 2014 Feb.

Abstract

In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Keywords: Alemtuzumab; Biology; CLL; Chronic lymphocytic leukemia; Fludarabine; Young.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources